AI Analysis

How does GSGTF make money? Does GSGTF have pricing power? What's the Earnings Whisper? Will GSGTF profit more as the business scales? What is GSGTF's management track record? Is GSGTF's current price justified?

GenSight Biologics S.A.

$0.09 -$0.10 (-52.66%)

OTC · 14 Sep 2026 20:00 UTC

Previous Close

$0.09

Day Range

$0.09$0.48

Year Range

$0.09$0.48

Market Cap

14.67M

AVG Volume

Trailing/Forward PE

-1.45/-

PEG ratio

-0.01

Dividend Yield

Next Earnings Date

2026-09-29

Primary Exchange

Other OTC

Free Cash Flow Yield

GSGTF Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-163.33%
Sep 26	-163.35%
Sep 26	-163.6%
Aug 26	-163.14%
Aug 26	-164.46%
Aug 26	-162.9%
Aug 26	-162.76%
Jul 26	-162.35%
Jul 26	-160.14%
Jul 26	-161.09%
Jul 26	-160.78%
Jul 26	-161.03%
Jun 26	-160.32%
Jun 26	-161.42%
Jun 26	-77.13%
Jun 26	-76.81%
May 26	-77.71%
May 26	-77.34%
May 26	-77.52%
May 26	-78.58%
May 26	-78.14%
Apr 26	-78.15%
Apr 26	-78.44%
Apr 26	-78.18%
Apr 26	-76.96%
Mar 26	-115.93%
Mar 26	-116.54%
Mar 26	-115.21%
Mar 26	-117.03%
Feb 26	-119.09%
Feb 26	-118.67%
Feb 26	-119.56%
Feb 26	-119.01%
Jan 26	-119.36%
Jan 26	-119.15%
Jan 26	-116.84%
Jan 26	-117.21%
Jan 26	-118.06%
Dec 25	-118.57%
Dec 25	-117.94%
Dec 25	-118.25%
Dec 25	-117.26%
Nov 25	-116.81%
Nov 25	-115.97%
Nov 25	-117.06%
Nov 25	-116.48%
Oct 25	-116.62%
Oct 25	-117.14%
Oct 25	-117.37%
Oct 25	-117.11%
Oct 25	-118.3%
Sep 25	-281.82%
Sep 25	-282.84%
Sep 25	-282.48%
Sep 25	-282.28%
Aug 25	-281.49%
Aug 25	-282.38%
Aug 25	-223.33%
Aug 25	-222.07%
Aug 25	-221.03%
Jul 25	-223.97%
Jul 25	-221.75%
Jul 25	-222.98%
Jul 25	-224.3%
Jun 25	-223.51%
Jun 25	-219.85%
Jun 25	-220.39%
Jun 25	-217.37%
May 25	-216.53%
May 25	-216.88%
May 25	-212.98%
May 25	-214.58%
May 25	-215.55%
Apr 25	-216.88%
Apr 25	-216.93%
Apr 25	-216.83%
Apr 25	-209.13%
Mar 25	-270.02%
Mar 25	-269.46%
Mar 25	-271.31%
Mar 25	-269.84%
Feb 25	-258.44%
Feb 25	-260.61%
Feb 25	-261.35%
Feb 25	-257.27%
Jan 25	-258.01%
Jan 25	-261.37%
Jan 25	-255.81%
Jan 25	-255.21%
Jan 25	-256.79%
Dec 24	-194.72%
Dec 24	-194.82%
Dec 24	-196.21%
Dec 24	-197.4%
Nov 24	-197.61%
Nov 24	-194.66%
Nov 24	-196.92%
Nov 24	-200.23%
Nov 24	-202.53%
Oct 24	-201.7%

Price to Sales

GSGTF Price to Sales by quarter
Period	Price to Sales
Sep 26	9.78
Sep 26	9.77
Sep 26	9.76
Aug 26	9.79
Aug 26	9.71
Aug 26	9.8
Aug 26	9.81
Jul 26	9.83
Jul 26	9.97
Jul 26	9.91
Jul 26	9.93
Jul 26	9.92
Jun 26	9.96
Jun 26	9.89
Jun 26	20.7
Jun 26	20.79
May 26	20.55
May 26	20.64
May 26	20.6
May 26	20.32
May 26	20.43
Apr 26	20.43
Apr 26	20.36
Apr 26	20.42
Apr 26	20.75
Mar 26	16.75
Mar 26	16.66
Mar 26	16.85
Mar 26	16.59
Feb 26	16.3
Feb 26	16.36
Feb 26	16.24
Feb 26	16.31
Jan 26	16.26
Jan 26	16.29
Jan 26	16.61
Jan 26	16.56
Jan 26	16.44
Dec 25	16.37
Dec 25	16.46
Dec 25	16.42
Dec 25	16.55
Nov 25	16.62
Nov 25	16.74
Nov 25	16.58
Nov 25	16.67
Oct 25	16.65
Oct 25	16.57
Oct 25	16.54
Oct 25	16.58
Oct 25	16.41
Sep 25	4.86
Sep 25	4.84
Sep 25	4.85
Sep 25	4.85
Aug 25	4.86
Aug 25	4.85
Aug 25	6.13
Aug 25	6.17
Aug 25	6.19
Jul 25	6.11
Jul 25	6.17
Jul 25	6.14
Jul 25	6.1
Jun 25	6.13
Jun 25	6.23
Jun 25	6.21
Jun 25	6.3
May 25	6.32
May 25	6.31
May 25	6.43
May 25	6.38
May 25	6.35
Apr 25	6.31
Apr 25	6.31
Apr 25	6.31
Apr 25	6.55
Mar 25	5.08
Mar 25	5.09
Mar 25	5.05
Mar 25	5.08
Feb 25	5.3
Feb 25	5.26
Feb 25	5.24
Feb 25	5.33
Jan 25	5.31
Jan 25	5.24
Jan 25	5.36
Jan 25	5.37
Jan 25	5.34
Dec 24	7.04
Dec 24	7.03
Dec 24	6.98
Dec 24	6.94
Nov 24	6.94
Nov 24	7.04
Nov 24	6.96
Nov 24	6.84
Nov 24	6.77
Oct 24	6.79

Price to Book

GSGTF Price to Book by quarter
Period	Price to Book
Mar 23	41.66
Mar 23	42.02
Mar 23	42.14
Mar 23	42.15
Feb 23	42.51
Feb 23	41.91
Feb 23	41.98
Feb 23	41.53
Jan 23	41.24
Jan 23	41.3
Jan 23	41.38
Jan 23	42.11
Dec 22	42.55
Dec 22	42.91
Dec 22	43.04
Dec 22	43.23
Dec 22	43.21
Nov 22	43.79
Nov 22	44.11
Nov 22	43.99
Nov 22	45.72
Oct 22	45.7
Oct 22	46.18
Oct 22	52.05
Oct 22	51.96
Sep 22	51.66
Sep 22	10.5
Sep 22	10.16
Sep 22	10.13
Sep 22	10.23
Aug 22	10.2
Aug 22	13.75
Aug 22	13.46
Aug 22	13.56
Jul 22	13.5
Jul 22	13.51
Jul 22	13.69
Jul 22	13.56
Jul 22	13.25
Jun 22	13.08
Jun 22	13.15
Jun 22	13.12
Jun 22	12.88
May 22	12.86
May 22	13.08
May 22	13.26
May 22	13.08
Apr 22	13.09
Apr 22	12.79
Apr 22	12.75
Apr 22	12.69
Apr 22	12.5
Mar 22	5.75
Mar 22	5.72
Mar 22	5.8
Mar 22	5.78
Feb 22	5.61
Feb 22	5.59
Feb 22	5.57
Feb 22	5.52
Jan 22	5.38
Jan 22	5.86
Jan 22	7.87
Jan 22	7.91
Dec 21	7.91
Dec 21	7.93
Dec 21	8
Dec 21	7.94
Dec 21	7.94
Nov 21	7.94
Nov 21	7.97
Nov 21	9.83
Nov 21	9.72
Oct 21	9.74
Oct 21	9.66
Oct 21	9.7
Oct 21	9.72
Oct 21	9.7
Sep 21	25.32
Sep 21	25.29
Sep 21	25.13
Sep 21	16.3
Aug 21	24.22
Aug 21	21.7
Aug 21	21.53
Aug 21	21.59
Jul 21	24.08
Jul 21	25.86
Jul 21	21.51
Jul 21	25.39
Jul 21	24.35
Jun 21	28.99
Jun 21	29.15
Jun 21	28.84
Jun 21	25.83
May 21	26.79
May 21	26.21
May 21	29.54
May 21	29.49
Apr 21	28.65

No video analysis for this stock yet. Request one from our team.

News: GSGTF

businesswire.com · 8 Sep 2026

GenSight Biologics Provides September 2026 Business Updates

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided business updates covering the summer of 2026 and confirmed the publication date for the Company's financial statement covering the first half of 2026. Update on Manufacturing The manufacture of the engi.

defenseworld.net · 13 Aug 2026

Financial Analysis: Pyxis Oncology (NASDAQ:PYXS) and GenSight Biologics (OTCMKTS:GSGTF)

GenSight Biologics (OTCMKTS:GSGTF - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership. Insider and Institutional Ownership 39.1% of Pyxis Oncology

businesswire.com · 8 Jul 2026

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2026, and provided business updates. Cash Position as of June 30, 2026 GenSight Biologics' cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared t.